中国医药导报
中國醫藥導報
중국의약도보
CHINA MEDICAL HERALD
2014年
24期
12-15
,共4页
姚刚%赵继福%黄倩%于挺敏
姚剛%趙繼福%黃倩%于挺敏
요강%조계복%황천%우정민
降钙素基因相关肽%偏头痛%头痛宁胶囊
降鈣素基因相關肽%偏頭痛%頭痛寧膠囊
강개소기인상관태%편두통%두통저효낭
Calcitonin gene-related peptide%Migraine%Toutongning Capsule
目的：探讨头痛宁胶囊干预偏头痛大鼠，对模型大鼠中脑降钙素基因相关肽(CGRP)基因表达的影响，及头痛宁胶囊对内源性痛觉调制系统功能的干预作用。方法将24只健康成年Wistar大鼠随机分为对照组(A组)，偏头痛组(B组)，头痛宁胶囊对照组(C组)，头痛宁胶囊治疗组(D组)，每组6只。C、D组给予头痛宁胶囊0.375 g/(kg·d)灌胃7 d，之后B、D组大鼠制备硝酸甘油型偏头痛大鼠模型，造模2 h处死大鼠，取中脑组织。采用实时定量PCR检测各组大鼠中脑CGRP mRNA拷贝数。结果 A、B、C、D组大鼠中脑每250 ng总RNA中脑CGRP mRNA拷贝数分别为：(1.13±0.68)×104、(1.61±0.51)×104、(0.80±0.45)×104、(0.75±0.27)×104。 A组与B组、C组与D组大鼠中脑CGRP mRNA拷贝数比较，差异均无统计学意义(P>0.05)；C、D组大鼠中脑CGRP mRNA拷贝数明显低于B组，差异有统计学意义(P<0.05)。结论头痛宁胶囊可以降低偏头痛发作时中脑CGRP基因的表达，发挥治疗偏头痛的作用。
目的：探討頭痛寧膠囊榦預偏頭痛大鼠，對模型大鼠中腦降鈣素基因相關肽(CGRP)基因錶達的影響，及頭痛寧膠囊對內源性痛覺調製繫統功能的榦預作用。方法將24隻健康成年Wistar大鼠隨機分為對照組(A組)，偏頭痛組(B組)，頭痛寧膠囊對照組(C組)，頭痛寧膠囊治療組(D組)，每組6隻。C、D組給予頭痛寧膠囊0.375 g/(kg·d)灌胃7 d，之後B、D組大鼠製備硝痠甘油型偏頭痛大鼠模型，造模2 h處死大鼠，取中腦組織。採用實時定量PCR檢測各組大鼠中腦CGRP mRNA拷貝數。結果 A、B、C、D組大鼠中腦每250 ng總RNA中腦CGRP mRNA拷貝數分彆為：(1.13±0.68)×104、(1.61±0.51)×104、(0.80±0.45)×104、(0.75±0.27)×104。 A組與B組、C組與D組大鼠中腦CGRP mRNA拷貝數比較，差異均無統計學意義(P>0.05)；C、D組大鼠中腦CGRP mRNA拷貝數明顯低于B組，差異有統計學意義(P<0.05)。結論頭痛寧膠囊可以降低偏頭痛髮作時中腦CGRP基因的錶達，髮揮治療偏頭痛的作用。
목적：탐토두통저효낭간예편두통대서，대모형대서중뇌강개소기인상관태(CGRP)기인표체적영향，급두통저효낭대내원성통각조제계통공능적간예작용。방법장24지건강성년Wistar대서수궤분위대조조(A조)，편두통조(B조)，두통저효낭대조조(C조)，두통저효낭치료조(D조)，매조6지。C、D조급여두통저효낭0.375 g/(kg·d)관위7 d，지후B、D조대서제비초산감유형편두통대서모형，조모2 h처사대서，취중뇌조직。채용실시정량PCR검측각조대서중뇌CGRP mRNA고패수。결과 A、B、C、D조대서중뇌매250 ng총RNA중뇌CGRP mRNA고패수분별위：(1.13±0.68)×104、(1.61±0.51)×104、(0.80±0.45)×104、(0.75±0.27)×104。 A조여B조、C조여D조대서중뇌CGRP mRNA고패수비교，차이균무통계학의의(P>0.05)；C、D조대서중뇌CGRP mRNA고패수명현저우B조，차이유통계학의의(P<0.05)。결론두통저효낭가이강저편두통발작시중뇌CGRP기인적표체，발휘치료편두통적작용。
Objective To investigate the effects of Toutongning Capsule on Calcitonin gene-related peptide (CGRP) ex-pression in the midbrain of rats with migraine headache, and the intervention effect of Toutongning Capsule on the function of endogenous pain modulation system. Methods A total of 24 adult Wistar rats were divided into control group (group A), model group (group B), Toutongning Capsule control group (group C) and Toutongning Capsule treat-ment group (group D), with 6 rats in each group. Group C and group D were given the Toutongning Capsule 0.375 g/(kg·d) for 7 days. 2 hours following nitroglycerin injection, the midbrains of rats were isolated and the expression of CGR was detected by real-time quantitative PCR. Results CGRP mRNA levels (CGRP mRNA copies per 250 ng total RNA) in the rat midbrain of group A, B, C, D were (1.13±0.68)í104, (1.61±0.51)í104, (0.80±0.45)í104, (0.75±0.27)í104 respec-tively. CGRP mRNA levels were similar between group A and group B, group C and group D, there were no significant differences in the CGRP mRNA copy number in the rat midbrain (P>0.05). The CGRP mRNA levels were significant-ly lower in the group C and group D compared with the groups B, the difference was statistically significant (P<0.05). Conclusion The therapeutically beneficial effects of Toutongning Capsule to migraine headaches is ralated to downreg-ulation of calcitonin gene-related peptide mRNA expressions in the midbrain.
